MedTrace Logo

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2018-09-05

No results posted yet for this study

Summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.

Conditions

Interventions

DRUG

pioglitazone

Tablets, 45 mg/day.

DRUG

inhaled human insulin

Treat-to-target dose titration scheme, inhalation.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-29
Primary Completion
2008-03-18
Completion
2008-03-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00411892 on ClinicalTrials.gov